|
|
|
|
|
|
|
Fig. 3
The NDA review and approval process. |
|
|
|
|
|
|
|
|
are affordable. The result is a focus on fewer projects per company and pressure to focus on truly important drugs, e.g., AIDS or cancer. |
|
|
|
|
|
|
|
|
A. The Political and Regulatory Environment |
|
|
|
|
|
|
|
|
In 1994, most pharmaceutical companies showed weak-to-modest results, reflecting intense price competition, discounts to managed care organizations, patent expiration for major drugs (e.g., Tagamet, Naprosyn), and a weak European market [55]. |
|
|
|
|
|
|
|
|
In addition to intensified competitive rivalry and profit pressures, pharmaceutical companies will continue to face further government scrutiny and in- |
|
|
|
|
|
